Clinical Trial Update: Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of a Farnesyl Protein Transferase Inhibitor in leukemia and myelodysplastic syndromes has completed, sponsored by Merck Sharp & Dohme LLC. The u…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia
• Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Farnesyl Protein Transferase Inhibitor (FPTI)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Leukemia, Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: COMPLETED